A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 2063040)

Published in Br J Cancer on August 01, 1998

Authors

G C Jayson1, M Middleton, S M Lee, L Ashcroft, N Thatcher

Author Affiliations

1: CRC Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.

Articles cited by this

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J Natl Cancer Inst (1989) 1.02

alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol (1991) 0.99

A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma. Cancer Biother (1993) 0.95

Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer (1995) 0.93

Interferon-alpha and survival in renal cell cancer. Br J Urol (1995) 0.92

Immunotherapy of metastatic renal cell cancer. Ann Oncol (1996) 0.87

Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann Oncol (1996) 0.84

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J Immunother Emphasis Tumor Immunol (1993) 0.82

Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors. Anticancer Res (1996) 0.80

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol (1996) 0.79

Medical treatment of advanced renal cell carcinoma: present options and future directions. Cancer Treat Rev (1996) 0.79

Renal cell carcinoma. Curr Opin Oncol (1996) 0.79

Articles by these authors

The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Single-chain antigen-binding proteins. Science (1988) 5.29

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Wnt signalling required for expansion of neural crest and CNS progenitors. Nature (1997) 3.11

Essential protective roles of reactive astrocytes in traumatic brain injury. Brain (2006) 2.75

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71

Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70

Thoracic pedicle screw fixation in spinal deformities: are they really safe? Spine (Phila Pa 1976) (2001) 2.64

Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48

Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med (2001) 2.47

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30

Modulation of receptive field properties of thalamic somatosensory neurons by the depth of anesthesia. J Neurophysiol (1999) 2.27

Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18

Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17

Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J (2009) 2.15

Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci (1999) 2.02

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97

Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94

Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem (2001) 1.90

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol (2005) 1.80

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79

Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77

Comparison of surgical conditions during propofol or sevoflurane anaesthesia for endoscopic sinus surgery. Br J Anaesth (2007) 1.76

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA (2001) 1.74

IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol (1982) 1.73

Correlates of asthma morbidity in primary care. BMJ (1992) 1.72

Peak flow based asthma self-management: a randomised controlled study in general practice. British Thoracic Society Research Committee. Thorax (1995) 1.72

Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70

Paradoxical effects of acute ethanolism in experimental brain injury. J Neurosurg (1997) 1.64

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62

Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer (2001) 1.62

Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res (2000) 1.62

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61

Estimating population size for capture-recapture data when capture probabilities vary by time and individual animal. Biometrics (1992) 1.53

Comparison of motor-evoked potentials monitoring in response to transcranial electrical stimulation in subjects undergoing neurosurgery with partial vs no neuromuscular block. Br J Anaesth (2013) 1.53

Resistance exercise training and the orthostatic response. Eur J Appl Physiol Occup Physiol (1997) 1.50

Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology (2007) 1.47

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45

Cloning, expression, and chromosomal location of SHH and IHH: two human homologues of the Drosophila segment polarity gene hedgehog. Genomics (1995) 1.44

Spark erosion: a high production rate method for producing Bi(0.5)Sb(1.5)Te3 nanoparticles with enhanced thermoelectric performance. Nanotechnology (2012) 1.42

Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene (1998) 1.40

Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38

A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38

O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33

Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31

The neurochemical and metabolic cascade following brain injury: moving from animal models to man. J Neurotrauma (1995) 1.30

Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury. J Neurotrauma (2000) 1.30

CT features of lobular capillary hemangioma of the nasal cavity. AJNR Am J Neuroradiol (2009) 1.29

Restoration of thoracic kyphosis in the hypokyphotic spine: a comparison between multiple-hook and segmental pedicle screw fixation in adolescent idiopathic scoliosis. J Spinal Disord (1999) 1.29

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29

Indications of proximal thoracic curve fusion in thoracic adolescent idiopathic scoliosis: recognition and treatment of double thoracic curve pattern in adolescent idiopathic scoliosis treated with segmental instrumentation. Spine (Phila Pa 1976) (2000) 1.28

ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1994) 1.27

Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci (1999) 1.26

Characterization of tissue-specific LIM domain protein (FHL1C) which is an alternatively spliced isoform of a human LIM-only protein (FHL1). J Cell Biochem (2001) 1.26

Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer (1992) 1.22

Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol (2000) 1.18

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18

Trends in Asian American racial/ethnic intermarriage: a comparison of 1980 and 1990 census data. Sociol Perspect (1998) 1.18

Fluid percussion brain injury in the developing and adult rat: a comparative study of mortality, morphology, intracranial pressure and mean arterial blood pressure. Brain Res Dev Brain Res (1996) 1.18

Neutralization epitopes on the antigenic domain II of the Orientia tsutsugamushi 56-kDa protein revealed by monoclonal antibodies. Vaccine (2000) 1.17

Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17

Aldose reductase, NADPH and NADP+ in normal, galactose-fed and diabetic rat lens. Biochim Biophys Acta (1985) 1.17

Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J (2001) 1.17

Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. Clin Exp Immunol (1981) 1.16

Asian Americans: diverse and growing. Popul Bull (1998) 1.15

A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol (1981) 1.15

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer (1988) 1.14

Upper abdominal lymphadenopathy as first presentation of relapse, identified by ultrasonography, in patients treated for small cell (oat cell) bronchogenic carcinoma. Br J Dis Chest (1985) 1.14

Increased granulocyte-macrophage colony-stimulating factor mRNA instability in cord versus adult mononuclear cells is translation-dependent and associated with increased levels of A + U-rich element binding factor. Blood (1996) 1.13

Malignant transformation of condyloma acuminatum. A light microscopic and ultrastructural study. Am J Clin Pathol (1974) 1.12

Chlamydia trachomatis pneumonitis in the C57BL/KsJ mouse: pathologic and immunologic features. J Lab Clin Med (1982) 1.12

Structural and functional repetition in a marine mussel adhesive protein. Biotechnol Prog (1990) 1.12

Immunodiagnosis of clonorchiasis using a recombinant antigen. Korean J Parasitol (1998) 1.11

Increased cerebral uptake and oxidation of exogenous betaHB improves ATP following traumatic brain injury in adult rats. J Neurochem (2004) 1.11

Targeting asthma care in general practice using a morbidity index. BMJ (1992) 1.10

A case with intrahepatic double cancer: hepatocellular carcinoma and cholangiocarcinoma associated with multiple von Meyenburg complexes. Yonsei Med J (1999) 1.09

Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer (1991) 1.08

Large-scale recovery and purification of L-asparaginase from Erwinia carotovora. Appl Biochem Biotechnol (1986) 1.08

Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer (1999) 1.08

Naltrexone dampens ethanol-induced cardiovascular and hypothalamic- pituitary-adrenal axis activation. Neuropsychopharmacology (2001) 1.08

Inhibition of neocortical plasticity during development by a moderate concussive brain injury. J Neurotrauma (2000) 1.06

Contraction-sensitive skeletal muscle afferents inhibit arterial baroreceptor signalling in the nucleus of the solitary tract: role of intrinsic GABA interneurons. Neuroscience (2003) 1.06

Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05

Localization of a major allergen, Der p 2, in the gut and faecal pellets of Dermatophagoides pteronyssinus. Clin Exp Allergy (2000) 1.05

Melanoma: chemotherapy. Br Med Bull (1995) 1.04

Mouse liver glutathione S-transferases. Biochemical and immunological characterization. J Biol Chem (1981) 1.04

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax (2006) 1.04

G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer (1997) 1.04

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res (2002) 1.03

O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer (2000) 1.03

Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer (1985) 1.03